|
1
|
Pardanani A: Systemic mastocytosis in
adults: 2019 update on diagnosis, risk stratification and
management. Am J Hematol. 94:363–377. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Brockow K: Epidemiology, prognosis, and
risk factors in mastocytosis. Immunol Allergy Clin North Am.
34:283–295. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Valent P: Mast cell activation syndromes:
Definition and classification. Allergy. 68:417–424. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Valent P, Akin C, Arock M, Brockow K,
Butterfield JH, Carter MC, Castells M, Escribano L, Hartmann K,
Lieberman P, et al: Definitions, criteria and global classification
of mast cell disorders with special reference to mast cell
activation syndromes: A consensus proposal. Int Arch Allergy
Immunol. 157:215–225. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Runser LA, Gauer RL and Houser A: Syncope:
Evaluation and differential diagnosis. Am Fam Physician.
95:303–312. 2017.PubMed/NCBI
|
|
6
|
Brignole M, Moya A, de Lange FJ, Deharo
JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA,
Martín A, et al: 2018 ESC Guidelines for the diagnosis and
management of syncope. Eur Heart J. 39:1883–1948. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Murali MR, Castells MC, Song JY, Dudzinski
DM and Hasserjian RP: Case records of the Massachusetts General
Hospital. Case 9-2011. A 37-year-old man with flushing and
hypotension. N Engl J Med. 364:1155–1165. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Campbell DE and Mehr S: Fifty years of
allergy: 1965-2015. J Paediatr Child Health. 51:91–93.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Rubin de Celis Ferrari AC, Glasberg J and
Riechelmann RP: Carcinoid syndrome: Update on the pathophysiology
and treatment. Clinics (Sao Paulo). 73 (Suppl
1)(e490s)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Siddall E, Khatri M and Radhakrishnan J:
Capillary leak syndrome: Etiologies, pathophysiology, and
management. Kidney Int. 92:37–46. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ellis JM: Urticaria pigmentosa; a report
of a case with autopsy. Arch Pathol (Chic). 48:426–435.
1949.PubMed/NCBI
|
|
12
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Metcalfe DD: Mast cells and mastocytosis.
Blood. 112:946–956. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Arock M, Sotlar K, Akin C, Broesby-Olsen
S, Hoermann G, Escribano L, Kristensen TK, Kluin-Nelemans HC,
Hermine O, Dubreuil P, et al: KIT mutation analysis in mast cell
neoplasms: Recommendations of the European Competence Network on
Mastocytosis. Leukemia. 29:1223–1232. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pardanani A: Systemic mastocytosis in
adults: 2017 update on diagnosis, risk stratification and
management. Am J Hematol. 91:1146–1159. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kondo R, Gleixner KV, Mayerhofer M, Vales
A, Gruze A, Samorapoompichit P, Greish K, Krauth MT, Aichberger KJ,
Pickl WF, et al: Identification of heat shock protein 32 (Hsp32) as
a novel survival factor and therapeutic target in neoplastic mast
cells. Blood. 110:661–669. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tefferi A, Lim KH, Abdel-Wahab O, Lasho
TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG and
Levine RL: Detection of mutant TET2 in myeloid malignancies other
than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
Leukemia. 23:1343–1345. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Greene LW, Asadipooya K, Corradi PF and
Akin C: Endocrine manifestations of systemic mastocytosis in bone.
Rev Endocr Metab Disord. 17:419–431. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Johansson C, Roupe G, Lindstedt G and
Mellstrom D: Bone density, bone markers and bone radiological
features in mastocytosis. Age and ageing. 25:1–7. 1996.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lim KH, Tefferi A, Lasho TL, Finke C,
Patnaik M, Butterfield JH, McClure RF, Li CY and Pardanani A:
Systemic mastocytosis in 342 consecutive adults: Survival studies
and prognostic factors. Blood. 113:5727–5736. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Pardanani A, Lim KH, Lasho TL, Finke CM,
McClure RF, Li CY and Tefferi A: WHO subvariants of indolent
mastocytosis: Clinical details and prognostic evaluation in 159
consecutive adults. Blood. 115:150–151. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Valent P, Sillaber C, Baghestanian M,
Bankl HC, Kiener HP, Lechner K and Binder BR: What have mast cells
to do with edema formation, the consecutive repair and
fibrinolysis? Int Arch Allergy Immunol. 115:2–8. 1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Scherber RM and Borate U: How we diagnose
and treat systemic mastocytosis in adults. Br J Haematol.
180:11–23. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
van der Weide HY, van Westerloo DJ and van
den Bergh WM: Critical care management of systemic mastocytosis:
When every wasp is a killer bee. Crit Care. 19(238)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen G, Chen L, Qin X, Xie X, Li G and Xu
B: Systemic mastocytosis with recurrent anaphylactic shock and
multiple organ dysfunction failure. Clin Lab. 61:179–182.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chatterjee M, Sengupta S, Chakravartyr C,
Ramasubban S, Bhartia S, Khan S and Agarwal VK: Indolent systemic
mastocytosis manifesting as protracted anaphylactic shock. Indian J
Crit Care Med. 22:311–313. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kors JW, van Doormaal JJ and de Monchy JG:
Anaphylactoid shock following Hymenoptera sting as a presenting
symptom of systemic mastocytosis. J Intern Med. 233:255–258.
1993.PubMed/NCBI View Article : Google Scholar
|
|
28
|
van Anrooij B, Oude Elberink JNG, Span
LFR, de Monchy JGR, Rosati S, Mulder AB and Kluin-Nelemans JC:
Midostaurin in patients with indolent systemic mastocytosis: An
open-label phase 2 trial. J Allergy Clin Immunol. 142:1006–1008.e7.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lortholary O, Chandesris MO, Bulai
Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S,
Verstovsek S, Grattan C, et al: Masitinib for treatment of severely
symptomatic indolent systemic mastocytosis: A randomised,
placebo-controlled, phase 3 study. Lancet. 389:612–620.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hartmann K, Escribano L, Grattan C,
Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S,
Siebenhaar F, Lange M, et al: Cutaneous manifestations in patients
with mastocytosis: Consensus report of the European Competence
Network on Mastocytosis; the American Academy of Allergy, Asthma
& Immunology; and the European Academy of Allergology and
Clinical Immunology. J Allergy Clin Immunol. 137:35–45.
2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Valent P, Akin C, Hartmann K, Nilsson G,
Reiter A, Hermine O, Sotlar K, Sperr WR, Escribano L, George TI, et
al: Advances in the classification and treatment of mastocytosis:
Current status and outlook toward the future. Cancer Res.
77:1261–1270. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kristensen T, Vestergaard H and Møller MB:
Improved detection of the KIT D816V mutation in patients with
systemic mastocytosis using a quantitative and highly sensitive
real-time qPCR assay. J Mol Diagn. 13:180–188. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kayser S, Levis MJ and Schlenk RF:
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and
systemic mastocytosis. Expert Rev Clin Pharmacol. 10:1177–1189.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nakamura R, Chakrabarti S, Akin C, Robyn
J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD and
Barrett AJ: A pilot study of nonmyeloablative allogeneic
hematopoietic stem cell transplant for advanced systemic
mastocytosis. Bone Marrow Transplant. 37:353–358. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ustun C, Reiter A, Scott BL, Nakamura R,
Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, et al:
Hematopoietic stem-cell transplantation for advanced systemic
mastocytosis. J Clin Oncol. 32:3264–3274. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Theoharides TC, Valent P and Akin C: Mast
cells, mastocytosis, and related disorders. N Engl J Med.
373:163–172. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
de Mol CL, Hermans MA, Gerth van Wijk R,
van Hagen PM and van Daele PL: Routine abdominal ultrasonography
has limited value in the care for patients with indolent systemic
mastocytosis. Hematology. 22:544–547. 2017.PubMed/NCBI View Article : Google Scholar
|
